| Literature DB >> 26589705 |
Kaio Cesar Simiano Tavares1, Ana Christina de Oliveira Dias2, Cícera Regina Lazzarotto1, Saul Gaudencio Neto1, Igor de Sá Carneiro1, Felipe Ledur Ongaratto1, Antônio Frederico Michel Pinto2, Luís Henrique de Aguiar1, Carlos Enrique Mendez Calderón1, Jorge Roberto Toledo3, Fidel Ovidio Castro4, Diogenes Santiago Santos2, Jocelei Maria Chies2, Marcelo Bertolini1,5, Luciana Relly Bertolini6,7.
Abstract
Gaucher disease (GD) is an orphan disease characterized by the lack or incapacity of glucocerebrosidase (hGCase) to properly process glucosylceramide, resulting in its accumulation in vital structures of the human body. Enzyme replacement therapy supplies hGCase to GD patients with a high-cost recombinant enzyme produced in vitro in mammalian or plant cell culture. In this study, we produced hGCase through the direct injection of recombinant adenovirus in the mammary gland of a non-transgenic goat. The enzyme was secreted in the milk during six days at a level up to 111.1 ± 8.1 mg/L, as identified by mass spectrometry, showing high in vitro activity. The milk-produced hGCase presented a mass correspondent to the intermediary high-mannose glycosylated protein, which could facilitate its delivery to macrophages through the macrophage mannose receptor. Further studies are underway to determine the in vivo delivery capacity of milk-hGCase, but results from this study paves the way toward the generation of transgenic goats constitutively expressing hGCase in the milk.Entities:
Keywords: Adenovirus; Gaucher disease; Glucocerebrosidase; Glycosylation; Milk; Recombinant protein
Mesh:
Substances:
Year: 2016 PMID: 26589705 DOI: 10.1007/s12033-015-9902-1
Source DB: PubMed Journal: Mol Biotechnol ISSN: 1073-6085 Impact factor: 2.695